Application of iridoid compound to preparation of ovarian cancer resistance medicament

Abstract

The invention provides the application of iridoid compound to the preparation of ovarian cancer resistance medicament. The iridoid compound is isovaleric acid base dihydro valerian element or isovaleric acid base dihydro valepotriate J which has the following structural formula. The experiments on the toxic and killing effect of the isovaleric acid base dihydro valerian element or the isovaleric acid base dihydro valepotriate J on the p 53 wild ovarian cancer cells A2780, the p53 mutated OVCAR-3 cells and the normal ovarian cells IOSE144 show that the isovaleric acid base dihydro valerian element or the isovaleric acid base dihydro valepotriate J has the selective toxic and killing effect on the ovarian cancer cells and can inhibit the proliferation of ovarian cancer cells and kill the ovarian cancer cells. The iridoid compound can be used as the active component to prepare the ovarian cancer resistance medicament. The invention provides the novel ovarian cancer treatment medicament for the clinical treatment of the ovarian cancer and brings the joyous news to the patients with the ovarian cancer. The iridoid compound has higher application value.

Description

technical field The invention relates to medicines, in particular to the application of iridoid compounds in the preparation of anti-ovarian cancer medicines. Background technique Ovarian cancer is one of the common tumors of female reproductive organs. Ovarian cancer is the leading cause of death among various gynecological tumors, posing a serious threat to women's lives, and its five-year survival rate is only 25% to 30%. According to epidemiological statistics, ovarian cancer is more likely to occur in women with ovarian insufficiency, such as delayed menarche, early menopause, dysmenorrhea, celibacy, infertility, frequent induced abortion, and people with family history. Since the ovary is located in the deep part of the pelvic cavity, there may be no or mild symptoms in the early stage of the disease. Because ovarian cancer is asymptomatic in the early clinical stage, it is very difficult to distinguish its tissue type and benign from malignant. Only 30% of ovarian c...

AI Technical Summary

Problems solved by technology

Although the research on spider incense has reached a certain scale, the research on its chemi

Images